ARMP

News

prnewswire.comArmata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Updateprnewswire.comMay 13

prnewswire.comArmata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02prnewswire.comMay 7

prnewswire.comArmata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"prnewswire.comMay 4

prnewswire.comArmata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D.prnewswire.comApr 27

prnewswire.comArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Resultsprnewswire.comMar 25

Trade ARMP

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.

CEO: Deborah L. Birx
IPO Date: May 20, 1994

Market Data

Open: $6.94
High: $7.20
Low: $6.88
Volume: 15.3K
Avg Volume: 65.1K
52W High: $16.34
52W Low: $1.81

Valuation

Market Cap: $260M
Enterprise Value: $629M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-26M
Revenue: $4.9M
Net Income: $-174M
Cash: $8.7M
Debt: $288M

Events

EarningsAug 11

EPS est. -0.48